Michael Burry's Scion Asset Management ramped up its bets on three Chinese tech giants but also hedged its positions.
Merck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug from China's LaNova Medicines.Please watch the video at Investors.com - ...
Applied Materials reported fiscal fourth-quarter earnings that missed analysts’ expectations, sending shares lower after the ...
The prospect of another US-China trade war on Donald Trump’s return to the White House is largely viewed through the prism of ...